10.6084/m9.figshare.5722183.v1
Tomoyuki Hayashi
Tomoyuki
Hayashi
Taro Yamashita
Taro
Yamashita
Takeshi Terashima
Takeshi
Terashima
Tsuyoshi Suda
Tsuyoshi
Suda
Hikari Okada
Hikari
Okada
Yoshiro Asahina
Yoshiro
Asahina
Takehiro Hayashi
Takehiro
Hayashi
Yasumasa Hara
Yasumasa
Hara
Kouki Nio
Kouki
Nio
Hajime Sunagozaka
Hajime
Sunagozaka
Hajime Takatori
Hajime
Takatori
Kuniaki Arai
Kuniaki
Arai
Yoshio Sakai
Yoshio
Sakai
Tatsuya Yamashita
Tatsuya
Yamashita
Eishiro Mizukoshi
Eishiro
Mizukoshi
Masao Honda
Masao
Honda
Shuichi Kaneko
Shuichi
Kaneko
Additional file 2: Figure S2. of Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study
Springer Nature
2017
Hepatocellular carcinoma
Sorafenib
Hepatic arterial infusion chemotherapy
Cytokine
Chemokine
Growth factor
2017-12-19 05:00:00
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/Additional_file_2_Figure_S2_of_Serum_cytokine_profiles_predict_survival_benefits_in_patients_with_advanced_hepatocellular_carcinoma_treated_with_sorafenib_a_retrospective_cohort_study/5722183
Comparison of serum IL-5, CXCL9, and VGEF-A levels between long survivors and non-long survivors in the 2 cohorts. (PDF 117 kb)